Sun Pharma & ICGEB sign exclusive deal on dengue vaccine – ARTES adds experience in VLP development and production

NEW DELHI, India I October 19, 2016

International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma today announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans. ICGEB has developed a tailored recombinant virus-like-particle (VLP) based tetravalent dengue vaccine, containing host-receptor binding domain of envelope protein of all the four DENV serotypes. ICGEB has conducted pre-clinical studies over the past seven years and developed the existing Know-How and Patents for this dengue vaccine candidate.

Sun Pharma invests over US$ 300 million annually on research and development in pharmaceuticals and biologics. The Company will use its in-house expertise as well as expertise of its Associate company, ARTES Biotechnology GmbH, in development of dengue vaccine. ARTES will add their experience and proprietary know-how in production of VLP based vaccines from yeast production cell lines. Hep-B and HPV vaccines developed by ARTES are licensed to several companies worldwide and a Malaria vaccine program is sponsored by PATH (Malaria Vaccine Initiative). Taken together, the Company has past experience in development of Hep-B and Typhoid vaccines, as well as complex vaccines, such as HPV and Malaria.

 

For the full text, see: http://www.sunpharma.com/media/press-releases